{"organizations": [], "uuid": "6a93ea446a75cfc577971cea2a54d46aa4990e56", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bd-statement-on-fda-warning-letter/brief-bd-statement-on-fda-warning-letter-for-preanalytical-systems-business-unit-idUSFWN1P70OM", "country": "US", "domain_rank": 408, "title": "BRIEF-BD Statement On FDA Warning Letter For Preanalytical Systems Business Unit", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-12T16:35:00.000+02:00", "replies_count": 0, "uuid": "6a93ea446a75cfc577971cea2a54d46aa4990e56"}, "author": "", "url": "https://www.reuters.com/article/brief-bd-statement-on-fda-warning-letter/brief-bd-statement-on-fda-warning-letter-for-preanalytical-systems-business-unit-idUSFWN1P70OM", "ord_in_thread": 0, "title": "BRIEF-BD Statement On FDA Warning Letter For Preanalytical Systems Business Unit", "locations": [], "entities": {"persons": [{"name": "preanalytica", "sentiment": "negative"}, {"name": "becton dickinson", "sentiment": "none"}, {"name": "becton dickinson", "sentiment": "none"}], "locations": [], "organizations": [{"name": "preanalytical systems business unit", "sentiment": "negative"}, {"name": "fda", "sentiment": "negative"}, {"name": "systems business unit reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 12, 2018 / 2:36 PM / in 27 minutes BRIEF-BD Statement On FDA Warning Letter For Preanalytical Systems Business Unit Reuters Staff \nJan 12 (Reuters) - Becton Dickinson And Co: \n* BD STATEMENT ON FDA WARNING LETTER FOR PREANALYTICAL SYSTEMS BUSINESS UNIT \n* BECTON DICKINSON - AFTER FDA INSPECTION IN JULY, TOOK ACTION THAT CO BELIEVED FULLY ADDRESSED AGENCY‘S INSPECTIONAL OBSERVATIONS \n* BECTON DICKINSON - “CAREFULLY REVIEWING” FDA‘S FEEDBACK OUTLINED IN LETTER WITH HIGHEST SENSE OF URGENCY, TO PROVIDE FULL RESPONSE ON OR BEFORE FEB 1 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-12T16:35:00.000+02:00", "crawled": "2018-01-12T17:04:16.003+02:00", "highlightTitle": ""}